It's always good to have friends in high places in Washington. And in the nation's capitol, you can always buy new ones.
In another indication of just how important the Medicare market is for biopharma companies, Abiomed revealed that it had paid the influential lobbying group Barbour Griffith & Rogers $100,000 in the first half of this year to lobby Congress and HHS on issues related to Medicare reimbursement and regulatory approval.
- read the Boston Globe report
ALSO: Coincidentally, Abiomed also announced that the FDA has OK'd a new study of a system designed to provide blood flow to patients undergoing surgery. Release
Related Articles:
Amgen ups lobbying efforts. Report
Biomedical researchers lobby against funding cuts. Report
Bay area biotechs plan new lobbying strategy. Report
Crawford signs on as Washington lobbyist. Report